Metex (Methotrexate)

Methotrexate acts as a folate antagonist. It competitively inhibits the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a co‑factor required for synthesis of purine nucleotides and thymidylate. This blockade reduces DNA, RNA and protein synthesis, particularly in rapidly dividing cells, leading to immunosuppression and antineoplastic effects.

The dose of Metex is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Dosing regimens differ for rheumatoid arthritis, psoriasis, leukemia or ectopic pregnancy, and may be administered weekly, bi‑weekly or as a single high‑dose infusion. Patients should follow the exact schedule provided by their healthcare professional.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnant women and should be stopped well before conception. Breastfeeding is also discouraged, as the drug is excreted in milk and may harm the infant. Alternative therapies should be considered for women of child‑bearing potential.

To place an order, visit the product page for Metex on the GNH India website (gnhindia.com), enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with import documentation.

Methotrexate, the active ingredient in Metex, is one of the most widely used antimetabolites. Compared with agents such as azathioprine or cyclophosphamide, methotrexate offers a well‑characterised efficacy profile for rheumatoid arthritis and certain cancers, often with a more predictable toxicity spectrum. Choice of therapy depends on disease, patient factors and physician experience.

Metex for injection must be stored at 2‑8 °C (refrigerated). It should be kept in its original packaging to protect from light, and must not be frozen or shaken vigorously. If the product reaches room temperature, it should be used within the time frame specified by the manufacturer, and any unused portion should be discarded according to local regulations.

Metex is supplied as a sterile solution for injection and can be given intramuscularly, intravenously or subcutaneously, depending on the clinical indication and physician preference. The injection is performed by a qualified healthcare professional using aseptic technique. Dosage volume and rate of administration are determined by the prescriber and may vary between weekly low‑dose regimens and high‑dose infusions.

The most serious adverse effects of methotrexate include bone‑marrow suppression leading to anemia, leukopenia or thrombocytopenia; severe hepatotoxicity that can progress to fibrosis or cirrhosis; and pulmonary toxicity such as interstitial pneumonitis. Patients should be monitored regularly with blood counts, liver function tests and respiratory assessment, and therapy should be stopped if any of these complications develop.

Metex is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, and patients with severe renal or hepatic impairment. It should also be avoided in patients with active infections, uncontrolled immune disorders, or those receiving live vaccines. Clinicians must evaluate each patient’s medical history and laboratory results before initiating therapy.